Tectonic Therapeutic, Inc. (TECX)

US — Healthcare Sector
Peers: ANRO  LRMR  CLLS  LYEL  AMRN  ACIU  DBVT  DRTS  SLN  ALDX 

Automate Your Wheel Strategy on TECX

With Tiblio's Option Bot, you can configure your own wheel strategy including TECX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point
TECX
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive

Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) patients. TECX is targeting CpcPH patients with PVR >3 in the ongoing phase 2 APEX study of PH-HFpEF, with topline data expected in 2026 and expansion into PH-ILD planned then also. TECX holds $268.4 million in cash, sufficient to fund operations into Q4 2028 and support multiple clinical milestones, including several catalysts.

Read More
image for news Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
TECX
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

About Tectonic Therapeutic, Inc. (TECX)

  • IPO Date 2018-06-21
  • Website https://tectonictx.com
  • Industry Biotechnology
  • CEO Alise S. Reicin
  • Employees 51
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.